Profile data is unavailable for this security.
About the company
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
- Revenue in USD (TTM)4.39m
- Net income in USD-135.38m
- Incorporated2004
- Employees202.00
- LocationPrecigen Inc20374 SENECA MEADOWS PARKWAYGERMANTOWN 20876United StatesUSA
- Phone+1 (301) 556-9900
- Websitehttps://precigen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Greenwich Lifesciences Inc | 0.00 | -10.22m | 186.26m | 3.00 | -- | 31.52 | -- | -- | -0.7942 | -0.7942 | 0.00 | 0.4496 | 0.00 | -- | -- | 0.00 | -112.41 | -36.43 | -123.67 | -38.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.63 | -- | -- | -- |
| Mediwound Ltd | 20.14m | -19.97m | 189.52m | 100.00 | -- | 9.13 | -- | 9.41 | -2.16 | -2.16 | 2.18 | 1.92 | 0.3311 | 5.53 | 6.55 | 201,410.00 | -32.83 | -24.48 | -49.28 | -32.92 | 13.25 | 43.27 | -99.17 | -38.43 | 1.51 | -3.26 | 0.2623 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
| Scilex Holding Co | 50.83m | -171.53m | 193.71m | 113.00 | -- | -- | -- | 3.81 | -1.40 | -1.40 | 0.4425 | -1.77 | 0.4401 | 5.22 | 1.55 | 484,123.80 | -102.93 | -- | -- | -- | 68.24 | -- | -233.88 | -- | 0.1853 | -3.72 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| Amylyx Pharmaceuticals Inc | 298.76m | -165.87m | 196.08m | 384.00 | -- | 0.7503 | -- | 0.6563 | -2.45 | -2.45 | 4.34 | 3.84 | 0.7605 | 3.69 | 15.91 | 778,026.10 | -42.22 | -- | -50.91 | -- | 84.64 | -- | -55.52 | -- | 4.66 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| Procaps Group SA | 414.10m | 52.20m | 204.21m | 5.50k | 3.47 | 5.18 | 2.93 | 0.4932 | 0.5209 | 0.5209 | 4.16 | 0.3491 | 0.854 | 1.87 | 3.38 | 75,290.18 | 10.77 | -- | 19.01 | -- | 55.04 | -- | 12.61 | -- | 0.9861 | -- | 0.8829 | -- | 0.0434 | -- | 142.18 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 130.30m | -14.23m | 239.82m | 147.00 | -- | -- | -- | 1.84 | -0.8136 | -0.8136 | 7.45 | -1.70 | 1.06 | 1.05 | 5.24 | 886,401.40 | -11.59 | -28.82 | -19.93 | -47.26 | 92.41 | 97.88 | -10.92 | -35.76 | 1.48 | -1.73 | 2.00 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Inhibrx Biosciences Inc | 1.85m | 1.63bn | 245.95m | 166.00 | 0.1402 | 1.12 | 0.1502 | 132.73 | 121.21 | 121.21 | 0.0434 | 15.15 | 0.0079 | -- | 4.86 | 11,162.65 | 693.63 | -77.06 | 815.31 | -93.91 | -- | -- | 88,264.55 | -1,590.91 | -- | -21.96 | 0.00 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
| Scpharmaceuticals Inc | 24.05m | -60.64m | 271.66m | 135.00 | -- | 21.22 | -- | 11.30 | -1.56 | -1.56 | 0.6187 | 0.256 | 0.2678 | 0.6563 | 6.23 | 178,133.30 | -67.52 | -38.23 | -75.77 | -42.31 | 71.15 | -- | -252.18 | -1,360.16 | 3.66 | -13.66 | 0.8121 | -- | -- | -- | -48.79 | -- | -- | -- |
| Sanara Medtech Inc | 72.41m | -6.57m | 272.12m | 107.00 | -- | 6.52 | -- | 3.76 | -0.7788 | -0.7788 | 8.62 | 4.77 | 1.10 | 1.86 | 8.13 | 676,731.00 | -10.16 | -17.73 | -12.08 | -22.07 | 89.73 | 88.08 | -9.23 | -17.13 | 1.49 | -4.88 | 0.2577 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Precigen Inc | 4.39m | -135.38m | 296.96m | 202.00 | -- | 6.09 | -- | 67.66 | -0.5407 | -0.5407 | 0.0176 | 0.1709 | 0.0313 | -- | 4.71 | 21,727.72 | -96.46 | -31.50 | -119.34 | -38.63 | -13.56 | 44.00 | -3,084.55 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Esperion Therapeutics Inc | 277.79m | -98.50m | 341.43m | 240.00 | -- | -- | -- | 1.23 | -0.8758 | -0.8758 | 1.84 | -1.77 | 0.9466 | 0.7763 | 5.49 | 1,157,450.00 | -33.56 | -69.45 | -64.71 | -101.81 | 81.82 | -- | -35.46 | -147.44 | 1.49 | 0.0972 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
| Emergent Biosolutions Inc | 1.10bn | -587.00m | 372.74m | 1.60k | -- | 0.9449 | -- | 0.3382 | -11.24 | -11.24 | 21.13 | 7.30 | 0.597 | 2.39 | 4.53 | 688,875.00 | -31.80 | -2.94 | -49.34 | -3.66 | 27.18 | 53.24 | -53.26 | -5.95 | 0.5438 | -1.87 | 0.6906 | -- | -6.10 | 6.05 | -259.40 | -- | -4.29 | -- |
| Theravance Biopharma Inc | 62.02m | -45.65m | 404.59m | 99.00 | -- | 2.09 | -- | 6.52 | -0.924 | -0.924 | 1.25 | 3.96 | 0.1534 | -- | 4.12 | 626,434.30 | -11.29 | -40.51 | -12.00 | -48.50 | -- | -- | -73.61 | -305.27 | -- | -- | 0.1305 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| CorMedix Inc | 806.12k | -53.12m | 404.71m | 82.00 | -- | 8.67 | -- | 502.04 | -0.9262 | -0.9262 | 0.0141 | 0.8355 | 0.014 | -- | -- | 9,830.73 | -92.57 | -54.84 | -110.35 | -62.32 | -64.79 | 6.18 | -6,589.09 | -18,323.42 | 4.43 | -- | 0.00 | -- | -100.00 | -- | -56.02 | -- | 46.27 | -- |
| Zevra Therapeutics Inc | 23.99m | -65.75m | 412.00m | 65.00 | -- | 10.12 | -- | 17.18 | -1.67 | -1.67 | 0.6106 | 0.7734 | 0.1919 | -- | 2.09 | 369,015.40 | -52.61 | -32.11 | -65.34 | -39.89 | 71.78 | -- | -274.10 | -128.42 | -- | -112.94 | 0.6423 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
Data as of Sep 19 2024. Currency figures normalised to Precigen Inc's reporting currency: US Dollar USD
16.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Patient Capital Management LLC (Invt Mgmt)as of 30 Jun 2024 | 18.17m | 6.31% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 9.09m | 3.16% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 6.65m | 2.31% |
| Geode Capital Management LLCas of 30 Jun 2024 | 3.10m | 1.08% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 2.84m | 0.99% |
| Iridian Asset Management LLCas of 30 Jun 2024 | 2.07m | 0.72% |
| D. E. Shaw & Co. LPas of 30 Jun 2024 | 1.73m | 0.60% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 1.18m | 0.41% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 1.10m | 0.38% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 1.03m | 0.36% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
